Please enable JavaScript.
Coggle requires JavaScript to display documents.
Icons (DIFICID (Product Availability Asset 15 Asset 14, Information &…
Icons
DIFICID
Product Availability
Information & Assistance
Disease-Related Patient Education Materials
Next-Day Delivery of Medications
Patient take DIFICID twice daily approximately every 12 hours
Patients can take DIFICID with or without food
10 days treatment
Narrow Spectrum
Head-to-head trials
Prescribing Information
Recurrent content
Dosing
Indication
Risk Factors
Antibiotic stwardship
Impact/interruption to critical treatments
Disease Information
Pathogensis
Recurrent CDI
Demonstrated Safety Profile:
Rising Rates of Recurrence
Functionalities
Specialized Pharmacy Network
Delivery type
Walk-In
Mail-Order
Lookup a Pharmacy
Call Ahead
Coupon
Activate and print or save
Request a coupon
Present the activated coupon
How to Activate
Call to Activate
Activate Online
Actual Coupon Icons
Savings Offer
Request a Representative
HCP
Patient
IDSA Guidelines
Metro no longer recommended
DIFICID is included
Updated
Updated IDSA Guidelines
Consider a different Regimen that was used in the Initial Episode
ZINPLAVA
Target toxin B to reduce CDI recurrence
One-time infusion that may be administrated in the outpatient setting
ZINPLAVA has a demonstrated safety profile
ZINPLAVA is not an antibiotic. ZINPLAVA is a human monoclonal antibody that targets toxin B to reduce rCDI
